Neuropsychology of Financial Capacity (NEUROFIN)

Istituto Auxologico Italiano

Status: Enrolling

Conditions: Stroke; Brain Tumor; Parkinson Disease

Treatments: Behavioral: Neuropsychological tests

Study type: Observational

Funder types: Other

Identifiers

NCT05791006

25C121

Details and patient eligibility

About

The present project aims to investigate the financial capacity in patients diagnosed with Parkinson's Disease or parkinsonism, brain tumor (glioma or meningioma) and cerebrovascular lesion (stroke), in order to evaluate the presence and degree of impairment, and the role of some factors as potential predictors of financial incapacity.

The term 'financial capacity' means both operations relating, for example, to asset management or investing money, and activities of daily life such as shopping or using small sums of money; these activities are mediated by different cognitive functions, from numerical and arithmetic skills to decision making. Financial capacity is, in fact, an instrumental activity of daily life (i.e. Instrumental Activity Of Daily Living, I-ADL) whose impairment negatively affects the functional autonomy of the individual, so as to be subject to legal protection.

To assess financial capacity, the Numerical Activities of Daily Living - Financial (NADL-F; Arcara et al., 2017) will be administered, a battery of tests aimed at investigating both financial performance and financial competence according to the most recent neuropsychological models proposed in the literature.

Enrollment: 99 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age > 18 years
• Clinical diagnosis of interest for clinical groups
• For stroke patients: disease duration > 1 month

Exclusion criteria

• Other brain disorders different from those of interest
• Sensory-motor deficits that could prevent neuropsychological assessment
• Language disorders that could prevent neuropsychological assessment
• Global cognitive impairment as indexed by MoCA < 26 or MMP < 22.85

Trial design

99 participants in 4 patient groups

Patients with Parkinson's Disease/Parkinsonisms

Treatment:

Behavioral: Neuropsychological tests

Patients with brain tumors

Treatment:

Behavioral: Neuropsychological tests

Patients with ischemic or haemorrhagic stroke

Treatment:

Behavioral: Neuropsychological tests

Healthy Controls

Treatment:

Behavioral: Neuropsychological tests